Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

被引：11

作者：

Nguyen, Anh Thu ^{[1
,2
]}

Kim, Hee-Kwon ^{[1
,2
]}

机构：

[1] Jeonbuk Natl Univ, Med Sch & Hosp, Dept Nucl Med, Jeonju 54907, South Korea

[2] Jeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Biomed Res Inst, Res Inst Clin Med, Jeonju 54907, South Korea

来源：

PHARMACEUTICS | 2023年 / 15卷 / 07期

基金：

新加坡国家研究基金会;

关键词：

hypoxia; tumor; radiopharmaceuticals; PET; SPECT; IN-VIVO EVALUATION; TC-99M LABELED COMPLEXES; INDUCIBLE FACTOR-I; BIOLOGICAL EVALUATION; FLUORESCENT-PROBES; PROSTATE-CANCER; IMAGING AGENT; F-18; FLUOROMISONIDAZOLE; MALIGNANT PROGRESSION; CLICK REACTION;

D O I：

10.3390/pharmaceutics15071840

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hypoxia, a deficiency in the levels of oxygen, is a common feature of most solid tumors and induces many characteristics of cancer. Hypoxia is associated with metastases and strong resistance to radio- and chemotherapy, and can decrease the accuracy of cancer prognosis. Non-invasive imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) using hypoxia-targeting radiopharmaceuticals have been used for the detection and therapy of tumor hypoxia. Nitroimidazoles are bioreducible moieties that can be selectively reduced under hypoxic conditions covalently bind to intracellular macromolecules, and are trapped within hypoxic cells and tissues. Recently, there has been a strong motivation to develop PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazole moieties for the visualization and treatment of hypoxic tumors. In this review, we summarize the development of some novel PET and SPECT radiotracers as radiopharmaceuticals containing nitroimidazoles, as well as their physicochemical properties, in vitro cellular uptake values, in vivo biodistribution, and PET/SPECT imaging results.

引用

页数：34

共 194 条

[1] The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research [J].